Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALFENTA vs METRETON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
Seasonal allergic conjunctivitis,Perennial allergic conjunctivitis,Other allergic ocular conditions
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Terminal elimination half-life is 24-36 hours; increased in renal impairment (up to 60 hours in anuria)
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Not extensively metabolized; primarily excreted unchanged in urine.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Renal (80-90% as unchanged drug and metabolites), biliary/fecal (10-20%)
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
75-85% bound to albumin and alpha-1-acid glycoprotein
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
0.5-1.0 L/kg; indicates moderate tissue distribution
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
Oral: 50-70% (first-pass metabolism); Intramuscular: 80-100%
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
Cr Cl 10-50 m L/min: administer every 12 hours; Cr Cl <10 m L/min: administer every 12-18 hours or consider dose reduction by 50%.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce dose by 75%.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
0.5-1 mg/kg intramuscularly or intravenously every 6-8 hours; maximum 25 mg per dose for children <40 kg.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
Start at lower end of dosing range (e.g., 0.5-1 mg/kg) with extended intervals (every 8-12 hours) due to decreased renal function and increased sensitivity.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
None
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Do not inject; for ophthalmic use only.,May cause transient burning or stinging.,Use with caution in patients with narrow-angle glaucoma.
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Hypersensitivity to any component of the formulation
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
Avoid excessive alcohol intake (increases risk of lactic acidosis). No specific food restrictions, but consistent carbohydrate intake is recommended to prevent hypoglycemia. Grapefruit may increase metformin levels (use caution).
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Pregnancy Category C: Fetal risk cannot be ruled out. First trimester: Increased risk of cleft palate and cardiac malformations due to corticosteroid component (prednisolone). Second and third trimesters: Potential for intrauterine growth restriction, adrenal suppression in neonate. Avoid use unless benefit outweighs risk.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
Prednisolone and chlorpheniramine (components of METRETON) are excreted into breast milk. M/P ratio for prednisolone is approximately 0.5-0.7. Low risk at maternal doses <20 mg/day; higher doses may cause infant adrenal suppression or growth delay. Consider alternative antihistamine with lower excretion.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
No specific dose adjustment required; use lowest effective dose for shortest duration. Pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism) may reduce efficacy of standard doses; monitor clinical response and consider dose titration. Avoid high-dose or prolonged therapy.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
METRETON is a fixed-dose combination of metformin and sitagliptin. Use with caution in patients with renal impairment (check e GFR before initiation; contraindicated if e GFR <30 m L/min/1.73 m²). Monitor for lactic acidosis, especially in hypoxic states or hepatic impairment. Discontinue temporarily before iodinated contrast imaging and for surgery. Assess for pancreatitis (discontinue if suspected). Do not use in type 1 diabetes or diabetic ketoacidosis. Dose adjustment of sitagliptin needed if e GFR 30-45 m L/min/1.73 m² (50 mg daily).
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
Take with meals to reduce gastrointestinal side effects.,Do not drink excessive alcohol while taking this medication.,Monitor for symptoms of lactic acidosis (unusual tiredness, muscle pain, trouble breathing, stomach pain) and pancreatitis (severe stomach pain, nausea, vomiting).,Inform your doctor if you become pregnant or plan to breastfeed.,Report any signs of allergic reaction (rash, hives, swelling of face/lips/throat) immediately.,Maintain adequate fluid intake, especially during illness or in hot weather.,Do not skip meals or drastically reduce carbohydrate intake without consulting your provider.
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALFENTA vs METRETON, answered by our medical review team.
ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. METRETON is a Antibiotic (Nitroimidazole) that works by Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALFENTA and METRETON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. The standard adult dose of METRETON is: 1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALFENTA and METRETON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. METRETON is classified as Category C. Pregnancy Category C: Fetal risk cannot be ruled out. First trimester: Increased risk of cleft palate and cardiac malformations due to corticosteroid component (prednisolone). Seco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.